 Molecular Partners AG NASDAQ: MOLN shares are trading lower again Thursday on continued weakness after the company recently said its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep. Vas Narasimhan, Novartis CEO, also. 